Aethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 299,300 shares, a decrease of 45.1% from the September 30th total of 544,800 shares. Based on an average daily trading volume, of 1,700,000 shares, the days-to-cover ratio is currently 0.2 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Aethlon Medical in a research report on Wednesday. They set a “sell” rating on the stock.
Get Our Latest Stock Analysis on Aethlon Medical
Aethlon Medical Stock Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10. During the same period in the prior year, the business posted ($1.30) earnings per share. Analysts forecast that Aethlon Medical will post -1.1 EPS for the current year.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- Industrial Products Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- Insider Trades May Not Tell You What You Think
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.